-
1
-
-
84876787550
-
The epidemiology of pancreatitis and pancreatic cancer
-
Yadav D, Lowenfels AB. The epidemiology of pancreatitis and pancreatic cancer. Gastroenterology 2013;144: 1252-61.
-
(2013)
Gastroenterology
, vol.144
, pp. 1252-1261
-
-
Yadav, D.1
Lowenfels, A.B.2
-
2
-
-
84862152967
-
Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: Meta-analysis and systematic review
-
Aroda VR, Henry RR, Han J, Huang W, DeYoung MB, Darsow T, et al. Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review. Clin Ther 2012;34:1247-58.e22.
-
(2012)
Clin Ther
, vol.34
-
-
Aroda, V.R.1
Henry, R.R.2
Han, J.3
Huang, W.4
Deyoung, M.B.5
Darsow, T.6
-
3
-
-
84859382440
-
Glycemic management of type 2 diabetes mellitus
-
Ismail-Beigi F. Glycemic management of type 2 diabetes mellitus. N Engl J Med 2012;366: 1319-27.
-
(2012)
N Engl J Med
, vol.366
, pp. 1319-1327
-
-
Ismail-Beigi, F.1
-
4
-
-
84859003663
-
Effects of glucagon-like peptide-1 receptor agonists on weight loss: Systematic review and meta-analyses of randomised controlled trials
-
Vilsboll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ 2012;344:d7771.
-
(2012)
BMJ
, vol.344
-
-
Vilsboll, T.1
Christensen, M.2
Junker, A.E.3
Knop, F.K.4
Gluud, L.L.5
-
5
-
-
84859174317
-
Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: Systematic review and meta-analysis
-
Karagiannis T, Paschos P, Paletas K, Matthews DR, Tsapas A. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. BMJ 2012;344:e1369.
-
(2012)
BMJ
, vol.344
-
-
Karagiannis, T.1
Paschos, P.2
Paletas, K.3
Matthews, D.R.4
Tsapas, A.5
-
6
-
-
84866268783
-
Management of hyperglycemia in type 2 diabetes: A patient-centered approach: Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
-
Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35: 1364-79.
-
(2012)
Diabetes Care
, vol.35
, pp. 1364-1379
-
-
Inzucchi, S.E.1
Bergenstal, R.M.2
Buse, J.B.3
Diamant, M.4
Ferrannini, E.5
Nauck, M.6
-
7
-
-
84892649479
-
Standards of medical care in diabetes-2014
-
American Diabetes Association
-
American Diabetes Association. Standards of medical care in diabetes-2014. Diabetes Care 2014;37:S14-80.
-
(2014)
Diabetes Care
, vol.37
-
-
-
10
-
-
84862129912
-
Consumer group calls for antidiabetes drug to be withdrawn
-
Lenzer J. Consumer group calls for antidiabetes drug to be withdrawn. BMJ 2012;344:e3259.
-
(2012)
BMJ
, vol.344
-
-
Lenzer, J.1
-
11
-
-
84879231610
-
A critical analysis of the clinical use of incretin-based therapies: The benefits by far outweigh the potential risks
-
Nauck MA. A critical analysis of the clinical use of incretin-based therapies: the benefits by far outweigh the potential risks. Diabetes Care 2013;36: 2126-32.
-
(2013)
Diabetes Care
, vol.36
, pp. 2126-2132
-
-
Nauck, M.A.1
-
12
-
-
84878185729
-
A critical analysis of the clinical use of incretin-based therapies: Are the GLP-1 therapies safe?
-
Butler PC, Elashoff M, Elashoff R, Gale EA. A critical analysis of the clinical use of incretin-based therapies: are the GLP-1 therapies safe? Diabetes Care 2013;36: 2118-25.
-
(2013)
Diabetes Care
, vol.36
, pp. 2118-2125
-
-
Butler, P.C.1
Elashoff, M.2
Elashoff, R.3
Gale, E.A.4
-
13
-
-
84879246350
-
Incretin therapy: Should adverse consequences have been anticipated?
-
Gale E. Incretin therapy: should adverse consequences have been anticipated? BMJ 2013;346:f3617.
-
(2013)
BMJ
, vol.346
-
-
Gale, E.1
-
14
-
-
84879237212
-
Has pancreatic damage from glucagon suppressing diabetes drugs been underplayed?
-
Cohen D. Has pancreatic damage from glucagon suppressing diabetes drugs been underplayed? BMJ 2013;346:f3680.
-
(2013)
BMJ
, vol.346
-
-
Cohen, D.1
-
15
-
-
84881235829
-
Potential harms of type 2 diabetes drugs have been ignored, finds BMJ investigation
-
Kmietowicz Z. Potential harms of type 2 diabetes drugs have been ignored, finds BMJ investigation. BMJ 2013;346:f3782.
-
(2013)
BMJ
, vol.346
-
-
Kmietowicz, Z.1
-
16
-
-
84880094856
-
Pressure mounts for companies to hand over data on antidiabetes drugs linked to pancreatic harm
-
Cohen D. Pressure mounts for companies to hand over data on antidiabetes drugs linked to pancreatic harm. BMJ 2013;346:f3900.
-
(2013)
BMJ
, vol.346
-
-
Cohen, D.1
-
17
-
-
84884492035
-
European drugs agency clashes with scientists over safety of GLP-1 drugs
-
Cohen D. European drugs agency clashes with scientists over safety of GLP-1 drugs. BMJ 2013;347:f4838.
-
(2013)
BMJ
, vol.347
-
-
Cohen, D.1
-
19
-
-
72449157026
-
Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas
-
Nachnani JS, Bulchandani DG, Nookala A, Herndon B, Molteni A, Pandya P, et al. Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas. Diabetologia 2010;53: 153-9.
-
(2010)
Diabetologia
, vol.53
, pp. 153-159
-
-
Nachnani, J.S.1
Bulchandani, D.G.2
Nookala, A.3
Herndon, B.4
Molteni, A.5
Pandya, P.6
-
20
-
-
84860567470
-
Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model
-
Gier B, Matveyenko AV, Kirakossian D, Dawson D, Dry SM, Butler PC. Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model. Diabetes 2012;61: 1250-62.
-
(2012)
Diabetes
, vol.61
, pp. 1250-1262
-
-
Gier, B.1
Matveyenko, A.V.2
Kirakossian, D.3
Dawson, D.4
Dry, S.M.5
Butler, P.C.6
-
21
-
-
67650245531
-
Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: Interactions with metformin
-
Matveyenko AV, Dry S, Cox HI, Moshtaghian A, Gurlo T, Galasso R, et al. Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin. Diabetes 2009;58: 1604-15.
-
(2009)
Diabetes
, vol.58
, pp. 1604-1615
-
-
Matveyenko, A.V.1
Dry, S.2
Cox, H.I.3
Moshtaghian, A.4
Gurlo, T.5
Galasso, R.6
-
22
-
-
78649658112
-
Exenatide does not evoke pancreatitis and attenuates chemically induced pancreatitis in normal and diabetic rodents
-
Tatarkiewicz K, Smith PA, Sablan EJ, Polizzi CJ, Aumann DE, Villescaz C, et al. Exenatide does not evoke pancreatitis and attenuates chemically induced pancreatitis in normal and diabetic rodents. Am J Physiol Endocrinol Metab 2010;299:E1076-86.
-
(2010)
Am J Physiol Endocrinol Metab
, vol.299
-
-
Tatarkiewicz, K.1
Smith, P.A.2
Sablan, E.J.3
Polizzi, C.J.4
Aumann, D.E.5
Villescaz, C.6
-
23
-
-
70349120958
-
Glucagon-like peptide-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice
-
Koehler JA, Baggio LL, Lamont BJ, Ali S, Drucker DJ. Glucagon-like peptide-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice. Diabetes 2009;58: 2148-61.
-
(2009)
Diabetes
, vol.58
, pp. 2148-2161
-
-
Koehler, J.A.1
Baggio, L.L.2
Lamont, B.J.3
Ali, S.4
Drucker, D.J.5
-
24
-
-
84860577431
-
The human GLP-1 analog liraglutide and the pancreas: Evidence for the absence of structural pancreatic changes in three species
-
Nyborg NC, Molck AM, Madsen LW, Knudsen LB. The human GLP-1 analog liraglutide and the pancreas: evidence for the absence of structural pancreatic changes in three species. Diabetes 2012;61: 1243-9.
-
(2012)
Diabetes
, vol.61
, pp. 1243-1249
-
-
Nyborg, N.C.1
Molck, A.M.2
Madsen, L.W.3
Knudsen, L.B.4
-
25
-
-
79959559653
-
Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1 based therapies
-
Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1 based therapies. Gastroenterology 2011;141: 150-6.
-
(2011)
Gastroenterology
, vol.141
, pp. 150-156
-
-
Elashoff, M.1
Matveyenko, A.V.2
Gier, B.3
Elashoff, R.4
Butler, P.C.5
-
27
-
-
77950473647
-
-
US Food and Drug Administration. US Public Law 110-85 section 801
-
US Food and Drug Administration. Food and Drug Administration Amendments Act (FDAAA) of 2007. US Public Law 110-85 section 801. www.gpo.gov/fdsys/pkg/ PLAW- 110publ85/pdf/PLAW-110publ85.pdf.
-
Food and Drug Administration Amendments Act (FDAAA) of 2007
-
-
-
29
-
-
84855985042
-
Specific instructions for estimating unclearly reported blinding status in randomized trials were reliable and valid
-
Akl EA, Sun X, Busse JW, Johnston BC, Briel M, Mulla S, et al. Specific instructions for estimating unclearly reported blinding status in randomized trials were reliable and valid. J Clin Epidemiol 2012;65: 262-7.
-
(2012)
J Clin Epidemiol
, vol.65
, pp. 262-267
-
-
Akl, E.A.1
Sun, X.2
Busse, J.W.3
Johnston, B.C.4
Briel, M.5
Mulla, S.6
-
30
-
-
13644257725
-
-
Wells GA SB, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of non-randomized studies in meta-analysis. www. ohri.ca/programs/clinical-epidemiology/oxford.asp.
-
The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Non-randomized Studies in Meta-analysis
-
-
Wells, G.A.S.B.1
O'Connell, D.2
Peterson, J.3
Welch, V.4
Losos, M.5
-
32
-
-
33846260745
-
Much ado about nothing: A comparison of the performance of meta-analytical methods with rare events
-
DOI 10.1002/sim.2528
-
Bradburn MJ, Deeks JJ, Berlin JA, Russell Localio A. Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Stat Med 2007;26: 53-77. (Pubitemid 46099417)
-
(2007)
Statistics in Medicine
, vol.26
, Issue.1
, pp. 53-77
-
-
Bradburn, M.J.1
Deeks, J.J.2
Berlin, J.A.3
Localio, A.R.4
-
33
-
-
84890613528
-
Special topics in statistics
-
Higgins JPT, Green S, eds., Cochrane Collaboration
-
Higgins JPT Deeks JJ, Altman DG. Special topics in statistics. In: Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions. Version 5.1.0. Cochrane Collaboration, 2011.
-
(2011)
Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0
-
-
Higgins, J.P.T.1
Deeks, J.J.2
Altman, D.G.3
-
34
-
-
0034685429
-
Meta-analysis of observational studies in epidemiology: A proposal for reporting
-
Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA 2000;283: 2008-12. (Pubitemid 30214957)
-
(2000)
Journal of the American Medical Association
, vol.283
, Issue.15
, pp. 2008-2012
-
-
Stroup, D.F.1
Berlin, J.A.2
Morton, S.C.3
Olkin, I.4
Williamson, G.D.5
Rennie, D.6
Moher, D.7
Becker, B.J.8
Sipe, T.A.9
Thacker, S.B.10
-
35
-
-
69449100622
-
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
-
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009;339:b2535.
-
(2009)
BMJ
, vol.339
-
-
Moher, D.1
Liberati, A.2
Tetzlaff, J.3
Altman, D.G.4
-
36
-
-
84874296660
-
Long-term safety of linagliptin monotherapy in Japanese patients with type 2 diabetes
-
Araki E, Kawamori R, Inagaki N, Watada H, Hayashi N, Horie Y, et al. Long-term safety of linagliptin monotherapy in Japanese patients with type 2 diabetes. Diabetes Obes Metab 2013;15: 364-71.
-
(2013)
Diabetes Obes Metab
, vol.15
, pp. 364-371
-
-
Araki, E.1
Kawamori, R.2
Inagaki, N.3
Watada, H.4
Hayashi, N.5
Horie, Y.6
-
37
-
-
84873263426
-
Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: An 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension
-
Barnett AH, Patel S, Harper R, Toorawa R, Thiemann S, von Eynatten M, et al. Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension. Diabetes Obes Metab 2012;14: 1145-54.
-
(2012)
Diabetes Obes Metab
, vol.14
, pp. 1145-1154
-
-
Barnett, A.H.1
Patel, S.2
Harper, R.3
Toorawa, R.4
Thiemann, S.5
Von Eynatten, M.6
-
38
-
-
77955573674
-
Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): A randomised trial
-
Bergenstal RM, Wysham C, MacConell L, Malloy J, Walsh B, Yan P, et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 2010;376: 431-9.
-
(2010)
Lancet
, vol.376
, pp. 431-439
-
-
Bergenstal, R.M.1
Wysham, C.2
Macconell, L.3
Malloy, J.4
Walsh, B.5
Yan, P.6
-
39
-
-
65949122087
-
One-year treatment with exenatide improves (beta)-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: A randomized, controlled trial
-
Bunck MC, Diamant M, Corner A, Eliasson B, Malloy JL, Shaginian RM, et al. One-year treatment with exenatide improves (beta)-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care 2009;32: 762-8.
-
(2009)
Diabetes Care
, vol.32
, pp. 762-768
-
-
Bunck, M.C.1
Diamant, M.2
Corner, A.3
Eliasson, B.4
Malloy, J.L.5
Shaginian, R.M.6
-
40
-
-
79551615182
-
Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: A randomized, controlled trial
-
Buse JB, Bergenstal RM, Glass LC, Heilmann CR, Lewis MS, Kwan AY, et al. Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med 2011;154: 103-12.
-
(2011)
Ann Intern Med
, vol.154
, pp. 103-112
-
-
Buse, J.B.1
Bergenstal, R.M.2
Glass, L.C.3
Heilmann, C.R.4
Lewis, M.S.5
Kwan, A.Y.6
-
41
-
-
79959211974
-
Safety and efficacy of saxagliptin in combination with submaximal sulphonylurea versus up-titrated sulphonylurea over 76 weeks
-
CV181040 Investigators
-
Chacra AR, Tan GH, Ravichandran S, List J, Chen R; CV181040 Investigators. Safety and efficacy of saxagliptin in combination with submaximal sulphonylurea versus up-titrated sulphonylurea over 76 weeks. Diab Vasc Dis Res 2011;8: 150-9.
-
(2011)
Diab Vasc Dis Res
, vol.8
, pp. 150-159
-
-
Chacra, A.R.1
Tan, G.H.2
Ravichandran, S.3
List, J.4
Chen, R.5
-
42
-
-
77953859640
-
Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): An open-label randomised trial
-
Diamant M, Van Gaal L, Stranks S, Northrup J, Cao D, Taylor K, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet 2010;375: 2234-43.
-
(2010)
Lancet
, vol.375
, pp. 2234-2243
-
-
Diamant, M.1
Van Gaal, L.2
Stranks, S.3
Northrup, J.4
Cao, D.5
Taylor, K.6
-
43
-
-
84861765116
-
Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: A randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono)
-
Fonseca VA, Alvarado-Ruiz R, Raccah D, Boka G, Miossec P, Gerich JE. Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono). Diabetes Care 2012;35: 1225-31.
-
(2012)
Diabetes Care
, vol.35
, pp. 1225-1231
-
-
Fonseca, V.A.1
Alvarado-Ruiz, R.2
Raccah, D.3
Boka, G.4
Miossec, P.5
Gerich, J.E.6
-
44
-
-
84864757433
-
2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: A randomised, double-blind, non-inferiority trial
-
Gallwitz B, Rosenstock J, Rauch T, Bhattacharya S, Patel S, von Eynatten M, et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. Lancet 2012;380: 475-83.
-
(2012)
Lancet
, vol.380
, pp. 475-483
-
-
Gallwitz, B.1
Rosenstock, J.2
Rauch, T.3
Bhattacharya, S.4
Patel, S.5
Von Eynatten, M.6
-
45
-
-
84862302997
-
Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): An open-label, randomised controlled trial
-
Gallwitz B, Guzman J, Dotta F, Guerci B, Simo R, Basson BR, et al. Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial. Lancet 2012;379: 2270-8.
-
(2012)
Lancet
, vol.379
, pp. 2270-2278
-
-
Gallwitz, B.1
Guzman, J.2
Dotta, F.3
Guerci, B.4
Simo, R.5
Basson, B.R.6
-
46
-
-
59449101432
-
Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): A randomised, 52-week, phase III, double-blind, parallel-treatment trial
-
Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olvera-Alvarez I, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009;373: 473-81.
-
(2009)
Lancet
, vol.373
, pp. 473-481
-
-
Garber, A.1
Henry, R.2
Ratner, R.3
Garcia-Hernandez, P.A.4
Rodriguez-Pattzi, H.5
Olvera-Alvarez, I.6
-
47
-
-
84866435806
-
Monotherapy with the once-weekly GLP-1 analogue dulaglutide for 12 weeks in patients with type 2 diabetes: Dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study
-
Grunberger G, Chang A, Garcia Soria G, Botros FT, Bsharat R, Milicevic Z. Monotherapy with the once-weekly GLP-1 analogue dulaglutide for 12 weeks in patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study. Diabet Med 2012;29: 1260-7.
-
(2012)
Diabet Med
, vol.29
, pp. 1260-1267
-
-
Grunberger, G.1
Chang, A.2
Garcia Soria, G.3
Botros, F.T.4
Bsharat, R.5
Milicevic, Z.6
-
48
-
-
84862813117
-
Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: A randomized, double-blind, placebo-controlled study
-
Haak T, Meinicke T, Jones R, Weber S, von Eynatten M, Woerle HJ. Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab 2012;14: 565-74.
-
(2012)
Diabetes Obes Metab
, vol.14
, pp. 565-574
-
-
Haak, T.1
Meinicke, T.2
Jones, R.3
Weber, S.4
Von Eynatten, M.5
Woerle, H.J.6
-
49
-
-
84863593432
-
Efficacy and safety of taspoglutide in patients with type 2 diabetes inadequately controlled with metformin plus pioglitazone over 24 weeks: T-Emerge 3 trial
-
T-Emerge 3 Study Group
-
Henry RR, Mudaliar S, Kanitra L, Woloschak M, Balena R; T-Emerge 3 Study Group. Efficacy and safety of taspoglutide in patients with type 2 diabetes inadequately controlled with metformin plus pioglitazone over 24 weeks: T-Emerge 3 trial. J Clin Endocrinol Metab 2012;97: 2370-9.
-
(2012)
J Clin Endocrinol Metab
, vol.97
, pp. 2370-2379
-
-
Henry, R.R.1
Mudaliar, S.2
Kanitra, L.3
Woloschak, M.4
Balena, R.5
-
50
-
-
79959217544
-
Safety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitus
-
CV181013 Investigators
-
Hollander PL, Li J, Frederich R, Allen E, Chen R; CV181013 Investigators. Safety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitus. Diab Vasc Dis Res 2011;8: 125-35.
-
(2011)
Diab Vasc Dis Res
, vol.8
, pp. 125-135
-
-
Hollander, P.L.1
Li, J.2
Frederich, R.3
Allen, E.4
Chen, R.5
-
51
-
-
84876268373
-
Effects of taspoglutide on glycemic control and body weight in obese patients with type 2 diabetes (T-emerge 7 study)
-
Hollander P, Lasko B, Barnett AH, Bengus M, Kanitra L, Pi-Sunyer FX, et al. Effects of taspoglutide on glycemic control and body weight in obese patients with type 2 diabetes (T-emerge 7 study). Obesity (Silver Spring) 2013;21: 238-47.
-
(2013)
Obesity (Silver Spring)
, vol.21
, pp. 238-247
-
-
Hollander, P.1
Lasko, B.2
Barnett, A.H.3
Bengus, M.4
Kanitra, L.5
Pi-Sunyer, F.X.6
-
52
-
-
84866144740
-
Efficacy and safety profile of exenatide once weekly compared with insulin once daily in Japanese patients with type 2 diabetes treated with oral antidiabetes drug(s): Results from a 26-week, randomized, open-label, parallel-group, multicenter, noninferiority study
-
e1
-
Inagaki N, Atsumi Y, Oura T, Saito H, Imaoka T. Efficacy and safety profile of exenatide once weekly compared with insulin once daily in Japanese patients with type 2 diabetes treated with oral antidiabetes drug(s): results from a 26-week, randomized, open-label, parallel-group, multicenter, noninferiority study. Clin Ther 2012;34:1892-908 e1.
-
(2012)
Clin Ther
, vol.34
, pp. 1892-1908
-
-
Inagaki, N.1
Atsumi, Y.2
Oura, T.3
Saito, H.4
Imaoka, T.5
-
53
-
-
67650490677
-
Exenatide exhibits dose-dependent effects on glycemic control over 12 weeks in Japanese patients with suboptimally controlled type 2 diabetes
-
Kadowaki T, Namba M, Yamamura A, Sowa H, Wolka AM, Brodows RG. Exenatide exhibits dose-dependent effects on glycemic control over 12 weeks in Japanese patients with suboptimally controlled type 2 diabetes. Endocr J 2009;56: 415-24.
-
(2009)
Endocr J
, vol.56
, pp. 415-424
-
-
Kadowaki, T.1
Namba, M.2
Yamamura, A.3
Sowa, H.4
Wolka, A.M.5
Brodows, R.G.6
-
54
-
-
77954360414
-
Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes
-
Kaku K, Rasmussen MF, Clauson P, Seino Y. Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes. Diabetes Obes Metab 2010;12: 341-7.
-
(2010)
Diabetes Obes Metab
, vol.12
, pp. 341-347
-
-
Kaku, K.1
Rasmussen, M.F.2
Clauson, P.3
Seino, Y.4
-
55
-
-
77955428835
-
Efficacy and tolerability of vildagliptin as an add-on to glimepiride in Japanese patients with type 2 diabetes mellitus
-
Kikuchi M, Haneda M, Koya D, Tobe K, Onishi Y, Couturier A, et al. Efficacy and tolerability of vildagliptin as an add-on to glimepiride in Japanese patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2010;89: 216-23.
-
(2010)
Diabetes Res Clin Pract
, vol.89
, pp. 216-223
-
-
Kikuchi, M.1
Haneda, M.2
Koya, D.3
Tobe, K.4
Onishi, Y.5
Couturier, A.6
-
56
-
-
84867142621
-
One-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal impairment
-
Kothny W, Shao Q, Groop PH, Lukashevich V. One-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal impairment. Diabetes Obes Metab 2012;14: 1032-9.
-
(2012)
Diabetes Obes Metab
, vol.14
, pp. 1032-1039
-
-
Kothny, W.1
Shao, Q.2
Groop, P.H.3
Lukashevich, V.4
-
57
-
-
62449129181
-
Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU)
-
Marre M, Shaw J, Brandle M, Bebakar WM, Kamaruddin NA, Strand J, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med 2009;26: 268-78.
-
(2009)
Diabet Med
, vol.26
, pp. 268-278
-
-
Marre, M.1
Shaw, J.2
Brandle, M.3
Bebakar, W.M.4
Kamaruddin, N.A.5
Strand, J.6
-
58
-
-
67649523294
-
Treatment with the human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes inadequately controlled with metformin alone: A double-blind placebo-controlled study
-
Nauck MA, Ratner RE, Kapitza C, Berria R, Boldrin M, Balena R. Treatment with the human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes inadequately controlled with metformin alone: a double-blind placebo-controlled study. Diabetes Care 2009;32: 1237-43.
-
(2009)
Diabetes Care
, vol.32
, pp. 1237-1243
-
-
Nauck, M.A.1
Ratner, R.E.2
Kapitza, C.3
Berria, R.4
Boldrin, M.5
Balena, R.6
-
59
-
-
84871093044
-
Taspoglutide, a once-weekly glucagon-like peptide1 analogue, vs. Insulin glargine titrated to target in patients with type 2 diabetes: An open-label randomized trial
-
Nauck M, Horton E, Andjelkovic M, Ampudia-Blasco FJ, Parusel CT, Boldrin M, et al. Taspoglutide, a once-weekly glucagon-like peptide1 analogue, vs. insulin glargine titrated to target in patients with type 2 diabetes: an open-label randomized trial. Diabet Med 2013;30: 109-13.
-
(2013)
Diabet Med
, vol.30
, pp. 109-113
-
-
Nauck, M.1
Horton, E.2
Andjelkovic, M.3
Ampudia-Blasco, F.J.4
Parusel, C.T.5
Boldrin, M.6
-
60
-
-
84873085581
-
Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study
-
Nauck M, Frid A, Hermansen K, Thomsen AB, During M, Shah N, et al. Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study. Diabetes Obes Metab 2013;15: 204-12.
-
(2013)
Diabetes Obes Metab
, vol.15
, pp. 204-212
-
-
Nauck, M.1
Frid, A.2
Hermansen, K.3
Thomsen, A.B.4
During, M.5
Shah, N.6
-
74
-
-
84898945450
-
-
Boehringer Ingelheim Pharmaceuticals. National Library of Medicine (US)
-
Boehringer Ingelheim Pharmaceuticals. Comprehensive add on study in Japan. National Library of Medicine (US), 2000. http://clinicaltrials.gov/show/ NCT01204294.
-
(2000)
Comprehensive Add on Study in Japan
-
-
-
76
-
-
84863230449
-
Efficacy and safety of saxagliptin in drug-naive Asian patients with type 2 diabetes mellitus: A randomized controlled trial
-
Pan CY, Yang W, Tou C, Gause-Nilsson I, Zhao J. Efficacy and safety of saxagliptin in drug-naive Asian patients with type 2 diabetes mellitus: a randomized controlled trial. Diabetes Metab Res Rev 2012;28: 268-75.
-
(2012)
Diabetes Metab Res Rev
, vol.28
, pp. 268-275
-
-
Pan, C.Y.1
Yang, W.2
Tou, C.3
Gause-Nilsson, I.4
Zhao, J.5
-
77
-
-
84873087943
-
Efficacy and tolerability of taspoglutide versus pioglitazone in subjects with type 2 diabetes uncontrolled with sulphonylurea or sulphonylurea-metformin therapy: A randomized, double-blind study (T-emerge 6)
-
Pratley RE, Urosevic D, Boldrin M, Balena R. Efficacy and tolerability of taspoglutide versus pioglitazone in subjects with type 2 diabetes uncontrolled with sulphonylurea or sulphonylurea-metformin therapy: a randomized, double-blind study (T-emerge 6). Diabetes Obes Metab 2013;15: 234-40.
-
(2013)
Diabetes Obes Metab
, vol.15
, pp. 234-240
-
-
Pratley, R.E.1
Urosevic, D.2
Boldrin, M.3
Balena, R.4
-
78
-
-
77955887980
-
Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with type 2 diabetes inadequately controlled with metformin: A randomized, double-blind, placebo-controlled trial
-
DR16012 Investigators
-
Ratner RE, Rosenstock J, Boka G; DR16012 Investigators. Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial. Diabet Med 2010;27: 1024-32.
-
(2010)
Diabet Med
, vol.27
, pp. 1024-1032
-
-
Ratner, R.E.1
Rosenstock, J.2
Boka, G.3
-
79
-
-
84859073016
-
Efficacy and safety of taspoglutide monotherapy in drug-naive type 2 diabetic patients after 24 weeks of treatment: Results of a randomized, double-blind, placebo-controlled phase 3 study (T-emerge 1)
-
Raz I, Hoekstra J, Fonseca V, Boldrin M, Kipnes M, Balena R, et al. Efficacy and safety of taspoglutide monotherapy in drug-naive type 2 diabetic patients after 24 weeks of treatment: results of a randomized, double-blind, placebo-controlled phase 3 study (T-emerge 1). Diabetes Care 2012;35: 485-7.
-
(2012)
Diabetes Care
, vol.35
, pp. 485-487
-
-
Raz, I.1
Hoekstra, J.2
Fonseca, V.3
Boldrin, M.4
Kipnes, M.5
Balena, R.6
-
80
-
-
70349664297
-
Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: A randomized controlled trial exploring weekly, biweekly, and monthly dosing
-
Rosenstock J, Reusch J, Bush M, Yang F, Stewart M. Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing. Diabetes Care 2009;32: 1880-6.
-
(2009)
Diabetes Care
, vol.32
, pp. 1880-1886
-
-
Rosenstock, J.1
Reusch, J.2
Bush, M.3
Yang, F.4
Stewart, M.5
-
81
-
-
70450173642
-
Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA1c without causing weight gain or increased hypoglycaemia
-
Rosenstock J, Rendell MS, Gross JL, Fleck PR, Wilson CA, Mekki Q. Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA1c without causing weight gain or increased hypoglycaemia. Diabetes Obes Metab 2009;11: 1145-52.
-
(2009)
Diabetes Obes Metab
, vol.11
, pp. 1145-1152
-
-
Rosenstock, J.1
Rendell, M.S.2
Gross, J.L.3
Fleck, P.R.4
Wilson, C.A.5
Mekki, Q.6
-
82
-
-
84866651423
-
Efficacy and safety of linagliptin 2.5mg twice daily versus 5mg once daily in patients with type 2 diabetes inadequately controlled on metformin: A randomised, double-blind, placebo-controlled trial
-
Ross SA, Rafeiro E, Meinicke T, Toorawa R, Weber-Born S, Woerle HJ. Efficacy and safety of linagliptin 2.5mg twice daily versus 5mg once daily in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, placebo-controlled trial. Curr Med Res Opin 2012;28: 1465-74.
-
(2012)
Curr Med Res Opin
, vol.28
, pp. 1465-1474
-
-
Ross, S.A.1
Rafeiro, E.2
Meinicke, T.3
Toorawa, R.4
Weber-Born, S.5
Woerle, H.J.6
-
83
-
-
69949117621
-
Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): A randomised controlled trial
-
Russell-Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, Antic S, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 2009;52: 2046-55.
-
(2009)
Diabetologia
, vol.52
, pp. 2046-2055
-
-
Russell-Jones, D.1
Vaag, A.2
Schmitz, O.3
Sethi, B.K.4
Lalic, N.5
Antic, S.6
-
84
-
-
84859013614
-
Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): A 26-week double-blind study
-
Russell-Jones D, Cuddihy RM, Hanefeld M, Kumar A, Gonzalez JG, Chan M, et al. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study. Diabetes Care 2012;35: 252-8.
-
(2012)
Diabetes Care
, vol.35
, pp. 252-258
-
-
Russell-Jones, D.1
Cuddihy, R.M.2
Hanefeld, M.3
Kumar, A.4
Gonzalez, J.G.5
Chan, M.6
-
85
-
-
77951044560
-
Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes
-
Seino Y, Rasmussen MF, Nishida T, Kaku K. Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes. Curr Med Res Opin 2010;26: 1013-22.
-
(2010)
Curr Med Res Opin
, vol.26
, pp. 1013-1022
-
-
Seino, Y.1
Rasmussen, M.F.2
Nishida, T.3
Kaku, K.4
-
86
-
-
84865996053
-
Efficacy and safety of alogliptin added to metformin in Japanese patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study
-
Seino Y, Miyata Y, Hiroi S, Hirayama M, Kaku K. Efficacy and safety of alogliptin added to metformin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study. Diabetes Obes Metab 2012;14: 927-36.
-
(2012)
Diabetes Obes Metab
, vol.14
, pp. 927-936
-
-
Seino, Y.1
Miyata, Y.2
Hiroi, S.3
Hirayama, M.4
Kaku, K.5
-
87
-
-
84865979163
-
Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia)
-
Seino Y, Min KW, Niemoeller E, Takami A, Abe N, Arai K, et al. Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia). Diabetes Obes Metab 2012;14: 910-7.
-
(2012)
Diabetes Obes Metab
, vol.14
, pp. 910-917
-
-
Seino, Y.1
Min, K.W.2
Niemoeller, E.3
Takami, A.4
Abe, N.5
Arai, K.6
-
88
-
-
79953035319
-
The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes: The EGO study
-
Umpierrez GE, Blevins T, Rosenstock J, Cheng C, Anderson JH, Bastyr EJ. The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes: the EGO study. Diabetes Obes Metab 2011;13: 418-25.
-
(2011)
Diabetes Obes Metab
, vol.13
, pp. 418-425
-
-
Umpierrez, G.E.1
Blevins, T.2
Rosenstock, J.3
Cheng, C.4
Anderson, J.H.5
Bastyr, E.J.6
-
89
-
-
78649709557
-
Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: A 16-week, randomized, double-blind, active control trial
-
Yang W, Chen L, Ji Q, Liu X, Ma J, Tandon N, et al. Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16-week, randomized, double-blind, active control trial. Diabetes Obes Metab 2011;13: 81-8.
-
(2011)
Diabetes Obes Metab
, vol.13
, pp. 81-88
-
-
Yang, W.1
Chen, L.2
Ji, Q.3
Liu, X.4
Ma, J.5
Tandon, N.6
-
90
-
-
67650066860
-
Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD)
-
Zinman B, Gerich J, Buse JB, Lewin A, Schwartz S, Raskin P, et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 2009;32: 1224-30.
-
(2009)
Diabetes Care
, vol.32
, pp. 1224-1230
-
-
Zinman, B.1
Gerich, J.2
Buse, J.B.3
Lewin, A.4
Schwartz, S.5
Raskin, P.6
-
91
-
-
79951704452
-
Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: A retrospective observational pharmacy claims analysis
-
Garg R, Chen W, Pendergrass M. Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis. Diabetes Care 2010;33: 2349-54.
-
(2010)
Diabetes Care
, vol.33
, pp. 2349-2354
-
-
Garg, R.1
Chen, W.2
Pendergrass, M.3
-
92
-
-
84867053241
-
Exenatide therapy and the risk of pancreatitis and pancreatic cancer in a privately insured population
-
Romley JA, Goldman DP, Solomon M, McFadden D, Peters AL. Exenatide therapy and the risk of pancreatitis and pancreatic cancer in a privately insured population. Diabetes Technol Ther 2012;14: 904-11.
-
(2012)
Diabetes Technol Ther
, vol.14
, pp. 904-911
-
-
Romley, J.A.1
Goldman, D.P.2
Solomon, M.3
McFadden, D.4
Peters, A.L.5
-
93
-
-
78650628953
-
Effectiveness of sitagliptin in asian Indian patients with type 2 diabetes-an Indian tertiary diabetes care center experience
-
Sudhakaran C, Kishore U, Anjana RM, Unnikrishnan R, Mohan V. Effectiveness of sitagliptin in asian Indian patients with type 2 diabetes-an Indian tertiary diabetes care center experience. Diabetes Technol Ther 2011;13: 27-32.
-
(2011)
Diabetes Technol Ther
, vol.13
, pp. 27-32
-
-
Sudhakaran, C.1
Kishore, U.2
Anjana, R.M.3
Unnikrishnan, R.4
Mohan, V.5
-
94
-
-
84876063836
-
Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: A population-based matched case-control study
-
Singh S, Chang HY, Richards TM, Weiner JP, Clark JM, Segal JB. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern Med 2013;173: 534-9.
-
(2013)
JAMA Intern Med
, vol.173
, pp. 534-539
-
-
Singh, S.1
Chang, H.Y.2
Richards, T.M.3
Weiner, J.P.4
Clark, J.M.5
Segal, J.B.6
-
95
-
-
84894903034
-
Incretin therapies and risk of hospital admission for acute pancreatitis in an unselected population of European patients with type 2 diabetes: A case-control study
-
Giorda CB, Picariello R, Nada E, Tartaglino B, Marafetti L, Costa G, et al. Incretin therapies and risk of hospital admission for acute pancreatitis in an unselected population of European patients with type 2 diabetes: a case-control study. Lancet Diabetes Endocrinol 2014;2: 111-5.
-
(2014)
Lancet Diabetes Endocrinol
, vol.2
, pp. 111-115
-
-
Giorda, C.B.1
Picariello, R.2
Nada, E.3
Tartaglino, B.4
Marafetti, L.5
Costa, G.6
-
96
-
-
67649304917
-
Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide
-
Dore DD, Seeger JD, Chan KA. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin 2009;25: 1019-27.
-
(2009)
Curr Med Res Opin
, vol.25
, pp. 1019-1027
-
-
Dore, D.D.1
Seeger, J.D.2
Chan, K.A.3
-
97
-
-
79954994764
-
A cohort study of acute pancreatitis in relation to exenatide use
-
Dore DD, Bloomgren GL, Wenten M, Hoffman C, Clifford CR, Quinn SG, et al. A cohort study of acute pancreatitis in relation to exenatide use. Diabetes Obes Metab 2011;13: 559-66.
-
(2011)
Diabetes Obes Metab
, vol.13
, pp. 559-566
-
-
Dore, D.D.1
Bloomgren, G.L.2
Wenten, M.3
Hoffman, C.4
Clifford, C.R.5
Quinn, S.G.6
-
98
-
-
84867212961
-
Relative risk of acute pancreatitis in initiators of exenatide twice daily compared with other anti-diabetic medication: A follow-up study
-
Wenten M, Gaebler JA, Hussein M, Pelletier EM, Smith DB, Girase P, et al. Relative risk of acute pancreatitis in initiators of exenatide twice daily compared with other anti-diabetic medication: a follow-up study. Diabet Med 2012;29: 1412-8.
-
(2012)
Diabet Med
, vol.29
, pp. 1412-1418
-
-
Wenten, M.1
Gaebler, J.A.2
Hussein, M.3
Pelletier, E.M.4
Smith, D.B.5
Girase, P.6
-
99
-
-
84879238656
-
Incretins and risk of neoplasia
-
Halfdanarson TR, Pannala R. Incretins and risk of neoplasia. BMJ 2013;346:f3750.
-
(2013)
BMJ
, vol.346
-
-
Halfdanarson, T.R.1
Pannala, R.2
-
100
-
-
84870508803
-
A meta-analysis of serious adverse events reported with exenatide and liraglutide: Acute pancreatitis and cancer
-
Alves C, Batel-Marques F, Macedo AF. A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer. Diabetes Res Clin Pract 2012;98: 271-84.
-
(2012)
Diabetes Res Clin Pract
, vol.98
, pp. 271-284
-
-
Alves, C.1
Batel-Marques, F.2
Macedo, A.F.3
-
101
-
-
84890564960
-
Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: A meta-analysis of randomized clinical trials
-
Monami M, Dicembrini I, Mannucci E. Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 2014;16: 48-56.
-
(2014)
Diabetes Obes Metab
, vol.16
, pp. 48-56
-
-
Monami, M.1
Dicembrini, I.2
Mannucci, E.3
|